In our study, we showed that the combined treatment using anti–PD-L1 and 2-ME2 induced an augmented antineoplastic potency in the Gstz1–/– mouse models, and the combination treatment exerted a more pronounced antitumor effect, assessed in terms of both tumor growth and survival, than each monotherapy. The gene discussed is GSTZ1; the disease is neoplasm.